Dr Reddys Laboratories Ltd (DRREDDY)
₹1,352.00
Mkt cap
₹1.13L Cr
P/E ratio
40.30
P/B
2.91
Div yield
0.59%
ROE
11.20%
ROCE
13.00%
EPS (TTM)
₹33.55
Book value
₹465
52W range
1,101–1,415
Sector
Healthcare
Price history
Previous close
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
NSE DRREDDYBSE 500124
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−4.45% from high₹1,352
₹1,101+22.80% from low₹1,415
Current
₹1,352.00
Prev close
₹1,345.00
Day
+0.52%
Price performance
1D
+0.52%
1W
+9.96%
1M
+8.00%
3M
+18.10%
6M
+1.67%
1Y
+5.67%
YTD
+7.63%
Financials
Revenue, profit & margin
P/E ratio
40.3×
DRREDDY is 17% above the sector median of 34.4×
DRREDDY40.3×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 | 8,698 | |
| Expenses | 4,894 | 5,214 | 5,283 | 5,566 | 5,962 | 6,108 | 6,530 | 6,398 | 6,818 | 6,866 | 7,164 | 7,240 | 6,975 | |
| Operating Profit | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,888 | 382 | 860 | 1,723 | |
| OPM % | 29% | 28% | 26% | 28% | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% | 20% | |
| Other Income | 319 | 219 | 201 | 193 | 314 | 154 | 528 | 290 | 330 | 271 | 480 | 356 | 156 | |
| Interest | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 | 125 | |
| Depreciation | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 | 527 | |
| Profit before tax | 1,917 | 1,829 | 1,605 | 1,883 | 1,917 | 1,874 | 2,005 | 1,905 | 1,745 | 1,543 | 200 | 553 | 1,228 | |
| Tax % | 23% | 24% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | -11% | 21% | 26% | |
| Net Profit | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 | 913 | |
| EPS in Rs | 17.77 | 16.56 | 15.70 | 16.69 | 15.05 | 16.94 | 19.09 | 16.99 | 16.14 | 14.50 | 2.65 | 5.32 | 11.08 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.26% · closed higher next day 33 of last 61
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 30 Jan '24◦ | 7 May '24◦ | 27 Jul '24◦ | 5 Nov '24◦ | 24 Jan '25 | 9 May '25◦ | 23 Jul '25◦ | 24 Oct '25◦ | 21 Jan '26◦ | 12 May '26◦ | 22 Jul '26◦ | 23 Oct '26◦ |
| Earnings day | +4.80% | −3.22% | −0.56% | +2.35% | −5.04% | +3.43% | +1.45% | +0.05% | +5.21% | −0.37% | −1.39% | +6.62% |
| +1 day | +2.61% | −6.08% | −1.08% | +1.19% | −7.12% | +4.43% | +2.45% | +0.45% | +6.77% | +2.65% | −2.63% | +6.55% |
| +5 days | +5.80% | −6.11% | −0.97% | −2.14% | −5.59% | +5.46% | +1.84% | −6.82% | +5.26% | +4.09% | −3.21% | — |
| +15 days | +8.70% | −4.10% | +1.26% | −5.49% | −5.10% | +7.94% | +1.04% | −3.10% | +9.58% | −0.20% | +1.96% | — |
| +30 days | +7.77% | −4.58% | −3.32% | +5.62% | −12.11% | +14.02% | +0.26% | −2.91% | +11.22% | +6.34% | −2.35% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 8 Per Share | 8.00 | 10 Jul '26 | 10 Jul '26 |
Shareholding
as of Sep 202626.63%Promoter
Promoters26.63%
FIIs20.30%0.37
DIIs31.87%0.12
Public20.99%0.23
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts50
PPTOct 2026RECOct 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026PPTMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptOct 2025PPTOct 2025RECOct 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025RECMay 2025TranscriptJan 2025RECJan 2025TranscriptNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 29 Oct - Transcript of Q2FY27 earnings call for quarter and half year ended September 30, 2026 uploaded.Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 28 Oct - USFDA classified FTO-SEZ Process Unit-02 inspection as VAI and officially closed it on October 28, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 24 OctAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 24 Oct - Audio and video recordings of October 23, 2026 earnings call for Q2 and half-year results released.General Update 23 Oct - Limited review reports filed for Q2 and H1 FY2026-27 unaudited financial results, dated October 23, 2026.